Authorities in Jiangxi, China approved two reagents manufactured by Tellgen (SHE:300642) subsidiary Jiangxi TellGen Life Technology, according to a Thursday filing with the Shenzhen bourse.
The two reagents help with diagnosing osteoporosis.
Related Articles
Asia
Correction: Manulife Financial Corp Files for Singapore Listing of SG$500 Million Worth of Bonds
(Corrects throughout to remove reference to Manulife US REIT and add Manulife Financial Corp's ticker)Manulife Financial Corp (HKG:0945) filed for the listing of SG$500 million worth of 2.88% subordinated bonds due 2036 on the Singapore bourse.The bonds will be listed and quoted in the Bonds Market on June 5, according to a filing with the Singapore Exchange on Thursday.
$HKG:0945$SGX:BTOU
Asia
BNK Financial Group Subsidiary's Former Employee Sentenced to 35 Years in Embezzlement Case
South Korea's Supreme Court ruled on a 35-year prison sentence for a former employee of BNK Financial Group (KRX:138930) subsidiary Kyongnam Bank, who had been charged with embezzlement under the Act on the Aggravated Punishment of Specific Economic Crimes.The ruling came after the court dismissed the defendant Lee OO's appeal on May 22, which confirmed the Seoul High Court's decision on Lee's remand, issued on Jan. 22.The former general manager was also ordered to pay an additional fine of 4.98 billion won, according to a Thursday filing with the Korea Exchange.Shares of BNK Financial Group rose nearly 1% at market close.
$KRX:138930
Asia
Indian Equities End Marginally Higher on Thursday Ahead of Central Bank's Policy Decision
Indian benchmark indices finished marginally higher on Thursday after another range-bound session, as investors remained cautious ahead of the central bank's monetary policy announcement.The BSE Sensex rose 13.84 points, or 0.02%, to close at 74,360.01, while the NSE Nifty 50 gained 10.95 points, or 0.1%, to settle at 23,416.55.Trading remained subdued as market participants avoided aggressive positions ahead of the Reserve Bank of India's policy outcome. Weak global cues and elevated crude oil prices also kept sentiment in check.In corporate developments, HFCL (NSE:HFCL, BOM:500183) approved a series of transactions to consolidate its defense and aerospace operations under HFCL Advance Systems. The company plans to invest 892.5 million rupees in the newly formed unit as part of a broader 1.75 billion-rupee funding round and will retain a majority stake upon completion.AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) said its board approved the surrender of its factory license for cancellation, following previously announced plans to exit its manufacturing facility and relinquish its manufacturing license.
$^BSE$^NSEI$BOM:500183$BOM:506820$NSE:ASTRAZEN$NSE:HFCL